share_log

NantHealth (NASDAQ:NH) Coverage Initiated at StockNews.com

NantHealth (NASDAQ:NH) Coverage Initiated at StockNews.com

NantHealth(納斯達克股票代碼:NH)的報道始於 StockNews
kopsource ·  2023/05/02 01:52

Research analysts at StockNews.com started coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a report issued on Sunday. The firm set a "hold" rating on the stock.

StockNews.com的研究分析師開始報道以下股票 NantHealth(納斯達克股票代碼:NH — 獲取評級) 在週日發佈的報告中。該公司對該股設定了 “持有” 評級。

NantHealth Price Performance

nanHealth 價格表現

NASDAQ:NH opened at $1.46 on Friday. The firm has a market capitalization of $11.20 million, a P/E ratio of -0.19 and a beta of 1.82. NantHealth has a 1-year low of $1.24 and a 1-year high of $11.85. The company's fifty day moving average price is $2.12 and its 200-day moving average price is $1.99.

納斯達克股票代碼:NH 週五開盤價爲 1.46 美元。該公司的市值爲1120萬美元,市盈率爲-0.19,beta值爲1.82。NantHealth的1年低點爲1.24美元,爲1年來的最高水平,爲11.85美元。該公司的五十天移動平均價格爲2.12美元,其200天移動平均線價格爲1.99美元。

Get
獲取
NantHealth
NanHealth
alerts:
警報:

Hedge Funds Weigh In On NantHealth

對沖基金對 nanHealth 進行權衡

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in shares of NantHealth in the second quarter valued at approximately $36,000. Millennium Management LLC acquired a new position in NantHealth during the 2nd quarter worth approximately $110,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of NantHealth during the 1st quarter worth approximately $170,000. 4.50% of the stock is owned by hedge funds and other institutional investors.

機構投資者最近買入和賣出了該公司的股票。高盛集團公司在第二季度收購了NanThealth股票的新頭寸,價值約爲36,000美元。千禧管理有限責任公司在第二季度收購了NanThealth的新職位,價值約11萬美元。最後,Atria Wealth Solutions Inc.在第一季度購買了價值約17萬美元的NantHealth股票的新股份。該股的4.50%由對沖基金和其他機構投資者持有。

NantHealth Company Profile

NanHealth 公司簡介

(Get Rating)

(獲取評分)

NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.

NantHealth, Inc是一家基於證據的個性化醫療保健公司,致力於爲癌症等關鍵疾病提供治療。該公司支持治療決策,改善患者預後,驗證治療方案,提供高質量的護理,降低成本,確保適當的報銷,並簡化實施和部署。

Featured Articles

精選文章

  • Get a free copy of the StockNews.com research report on NantHealth (NH)
  • Insiders Drive Volatility For Keurig Dr Pepper
  • After a 40% Drop, Analysts Remain Bullish on Impinj
  • Visa Charges Higher After Better-Than-Expected Q2 Report
  • onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
  • Can Teladoc Stock Be Resuscitated?
  • 免費獲取 StockNews.com 關於 NantHealth(NH)的研究報告的副本
  • 業內人士推動了Keurig Pepper博士的波動性
  • 在下跌40%之後,分析師仍然看好Impinj
  • 第二季度報告好於預期後,簽證費用上漲
  • onsemi將芯片股觸底,創下新高
  • Teladoc 股票能否復甦?

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

接收 NanHealth Daily 的新聞和收視率 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收NantHealth及相關公司最新新聞和分析師評級的簡明每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論